Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2006-07-07
2010-06-22
Yaen, Christopher H (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
Reexamination Certificate
active
07741040
ABSTRACT:
In certain aspects, the invention provides isolated SLC5A8 (also referred to as Hui1) nucleic acid molecules, which encode novel sodium solute symporter members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing SLC5A8 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a SLC5A8 gene has been introduced or disrupted. The invention still further provides isolated SLC5A8 proteins, fusion proteins, antigenic peptides, and anti-SLC5A8 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. In other aspects, the invention provides methods and compositions for detecting and treating SLC5A8-associated cancer. Differential methylation of the SLC5A8 nucleotide sequences has been observed in SLC5A8-associated cancer, such as colon cancer, breast cancer, thyroid cancer, or stomach cancer.
REFERENCES:
patent: 5786146 (1998-07-01), Herman et al.
patent: 6017704 (2000-01-01), Herman et al.
patent: 6200756 (2001-03-01), Herman et al.
patent: 6265171 (2001-07-01), Herman et al.
patent: 7214485 (2007-05-01), Belinsky et al.
patent: 2002/0127674 (2002-09-01), Yu et al.
patent: 2002/0156002 (2002-10-01), Curtis et al.
patent: 1 130 094 (2001-09-01), None
patent: WO 01/73030 (2001-10-01), None
patent: WO 02/18632 (2002-03-01), None
patent: WO 02/46415 (2002-06-01), None
patent: WO 02/50105 (2002-06-01), None
patent: WO 02/063002 (2002-08-01), None
patent: WO 02/079449 (2002-10-01), None
patent: WO 03/091448 (2003-11-01), None
patent: WO 03091448 (2003-11-01), None
Filetti, S. et al. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur. J. Endocrinol. 141, 443-457 (1999).
Reizer, J. et al. A functional superfamily of sodium/solute symporters. Bichem. Biophys. Acta. 1197, 133-166 (1994).
Swick, A.G. et al. Promoter-cDNA-directed heterologous protein expression inXenopus laevisoocytes. PNAS 89, 1812-1816 (1992).
Romero, M.F. et al. Cloning and Characterization of a Na+ -driven. J. Biol. Chem. 275, 24552-24559 (2000).
Sciortino, C.M. et al. Cation and voltage dependence of rat kidney electrogenic Na+ -HCO3-cotransporter, rkNBC, expressed in oocytes. Am. J. Physiol. 277, F611-623 (1999).
Herman, J.G. et al. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. PNAS 93, 9821-9826 (1996).
Kane, M.F. et al. Methylation of the hMLH1 Promoter Correlates with Lack of Expression of hMLH1 in Sporadic Colon Tumors and Mismatch Repair-defective Human Tumor Cell Lines. Cancer Res. 57, 808-11 (1997).
Gonzalgo, M.L. and Jones, P.A. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE). Nucleic Acids Res. 25, 2529-31 (1997).
Xiong, Z. and Laird, P.W. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 25, 2532-4 (1997).
Hibi, K. et al. Molecular Detection of Genetic Alterations in the Serum of Colorectal Cancer Patients. Cancer Res. 58, 1405-7 (1998).
Baylin, S.B. et al. Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia. Adv. Cancer Res., 72, 141-96 (1998).
Jones, P.A. et al. The DNA methylation paradox. Trends Genet. 15, 34-7 (1999).
Baylin, S. et al. Altered methylation patterns in cancer cell genomes: Cause or consequence? Cancer Cell 1, 299-305 (2002).
Feinberg, A.P. and Vogelstein, B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301, 89-92 (1983).
Veigl, M.L. et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. PNAS 95, 8698-702 (1998).
Grady, W.M. et al. Detection of Aberrantly Methylated hMLH1 Promoter DNA in the Serum of Patients with Microsatellite Unstable Colon Cancer. Cancer Res. 61, 900-2 (2001).
Usadel, H. et al. Quantitative Adenomatous Polyposis Coli Promoter Methylation Analysis in Tumor Tissue, Serum, and Plasma DNA of Patients with Lung Cancer. Cancer Res. 62, 371-5 (2002).
Costello, J.F. et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet. 24, 132-8 (2000).
Attwood, J.T. et al. DNA methylation and the regulation of gene transcription. Cell Mol. Life Sci. 59, 241-257 (2002).
Moinova, H.R. et al. HLTF gene silencing in human colon cancer. PNAS 99, 4562-7 (2002).
Siu, I.-M. et al. The Identification of Monoclonality in Human Aberrant Crypt Foci. Cancer Res. 59, 63-66 (1999).
Bird, R.P. Observation and Quantification of Aberrant Crypts in the Murine Colon Treated with a Colon Carcinogen: Preliminary Findings. Cancer Lett. 37, 147-51 (1987).
Pretlow, T.P. et al. Aberrant Crypts: Putative Preneoplastic Foci in Human Colonic Mucosa. Cancer Res. 51, 1564-7 (1991).
Herman, J.G. et al. Inactivation of the CDKN2/p16/MTS1 Gene is Frequently Associated with Aberrant DNA Methylation in all Common Human Cancers. Cancer Res. 55, 4525-4530 (1995).
Gonzalez-Zulueta, M. et al. Methylation of the 5′ CpG Island of the p16/CDKN2 Tumor Suppressor Gene in Normal and Transformed Human Tissues Correlates with Gene Silencing. Res. 55, 4531-4535 (Oct. 15, 1995).
Jeronimo, C. et al. Quantitation of GSTP1 Methylation in Non-neoplastic Prostatic Tissue and Organ-Confined Prostate Adenocarcinoma. J. Natl. Cancer Inst. 93, 1747-1752 (2001).
Smanik, P.A. et al. Cloning of the Human Sodium Iodide Symporter. Biochem. Biophys. Res. Commun. 226, 339-345 (1996).
Prasad, P.D. et al. Cloning and Functional Expression of a cDNA Encoding a Mammalian Sodium-dependent Vitamin Transporter Mediating the Uptake of Pantothenate, Biotin, and Lipoate. J. Biol. Chem. 273, 7501-7506 (1998).
Wright, E.M. et al. ‘Active’ Sugar Transport in Eukaryotes. J. Exp. Biol. 196, 197-212 (1994).
Bird, R.P. A novel methodological approach to study the level of specific protein and gene expression in aberrant crypt foci putative preneoplastic colonic lesions by Western blotting and RT-PCR. Cancer Lett. 116, 15-19 (1997).
Markowitz, S. et al. Inactivation of the Type II Tgf-$\beta$ Receptor in Colon Cancer Cells with Microsatellite Instability. Science 268, 1336-1338 (1995).
Willson, J.K.V. et al. Cell Culture of Human Colon Adenomas and Carcinomas. Cancer Res. 47, 2704-2713 (1987).
Li, H. et al. SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. PNAS 100(14), 6412-7 (2003).
Rodriguez, A.-M. et al. Identification and Characterization of a Putative Human Iodide Transporter Located at the Apical Membrane of Thyrocytes. J. Clin. Endocrinol. Metab. 87, 3500-3 (2002).
Chung, “Sodium Iodide Symporter: Its Role in Nuclear Medicine,” J. Nucl. Med., 43, 1188-200 (2002).
Jung, H. The sodium/substrate symporter family: structural and functional features. FEBS Letters 529, 73-77 (2002).
Rodriguez, et al., J. Clin. Endocrinol. Metab., 87, 3500-3 (2002).
Riedel, C. et al., “Journey of the iodide transporter NIS: from its molecular identification to its clinical role in cancer”, TIBS Trends in Biochemical Sciences, 26(8), pp. 490-496 (1002).
Ishikawa, N. et al., “SGLT gene expression in primary lung cancers and their metastatic lesions”, Japanese Journal of Cancer Research: Gann., 92(8), pp. 874-879 (2002).
Miyauchi, Seiji et al., “Functional identification of SLC5A8, a tumor suppressor down-regulated in colon cancer, as a Na+-coupled transporter for short-chain fatty acids”, Journal of Biological Chemistry, 279(14), pp. 13293-13296 (2004).
Ueno, Masako et al., “Aberrant methylation and histone deacetylation associated with silencing of SLC5A8 in gastric cancer”, Tumor Biology, 25(3), pp. 134-140 (2004).
Fleisher, A. S. et al., “Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1”, Cancer Research, 60(17), pp. 4864-4868 (2000).
Jubb, A. M. et al, “
Case Western Reserve University
Ropes & Gray LLP
Sang Hong
Yaen Christopher H
LandOfFree
Methods and compositions for detecting cancers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for detecting cancers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for detecting cancers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4237206